Mid-term outcomes of percutaneous pulmonary valve replacement with Edwards-Sapien bioprosthesis in native right ventricular outflow tract

Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40...

Descripción completa

Detalles Bibliográficos
Autores: Belahnech, Yassin|||0000-0003-0723-1023, Martí-Aguasca, Gerard, Dos Subira, Laura|||0000-0001-5821-4501, Betrián-Blasco, Pedro|||0000-0001-8891-5245, García del Blanco, Bruno|||0000-0002-4527-1600, Calvo-Barceló, Maria, Ródenas-Alesina, Eduard|||0000-0003-1638-7820, Pijuan-Domènech, Antonia|||0000-0003-0893-3692, Gran, Ferran|||0000-0001-9076-241X, Ferrer Menduiña, Queralt|||0000-0003-3177-4618, Giralt-García, Gemma, Miranda, Berta|||0000-0003-1617-1050, Gordon, Blanca, González-Fernández, Víctor, Barrabés, José A.|||0000-0001-7062-6277, Roses-Noguer, Ferran, Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:dnet:uabarcelona_::0a097a913f41bd3d11e26f660c977961
Acceso en línea:https://ddd.uab.cat/record/328375
https://dx.doi.org/urn:doi:10.1038/s41598-024-82336-4
Access Level:acceso abierto
Palabra clave:Cardiology
Congenital heart disease
Edwards Sapien
Interventional cardiology
Percutaneous pulmonary valve replacement
Pulmonary valve
Descripción
Sumario:Information on mid-term outcomes of percutaneous pulmonary valve replacement (PPVR) with the Edwards Sapien (ES) valve in the native right ventricular outflow tract (RVOT) are limited. This study assesses mid-term outcomes in 76 patients who underwent PPVR between 2016 and 2022, comparing native (40.8%) and non-native (59.2%) RVOTs. The primary endpoint was a composite of endocarditis, reinterventions, and cardiovascular death and secondary outcomes included prosthetic valve dysfunction (PVD), tricuspid regurgitation (TR), right ventricular ejection fraction (RVEF), and indexed ventricular volumes. The median patient age was 23.9 years. Pulmonary regurgitation was predominant in the native RVOT group (67.7%), while pulmonary stenosis or combined lesions were more common in the non-native group (90.9%). Procedural success was 98.7%. After a median follow-up of 3.3 years, there was no significant difference in freedom from the primary outcome between groups (87.1% native vs. 93.1% non-native, p = 0.875). Endocarditis and reinterventions occurred at 1.2 per 100 patient-years, and PVD at 3.19 per 100 patient-years, with no differences between groups. A 1-year reduction in ventricular volumes and TR was seen only in the non-native group, with no improvement in RVEF. Overall, PPVR with the ES valve demonstrates satisfactory mid-term outcomes in both native and non-native RVOTs.

Similares en LA Referencia